GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (NAS:TRAW) » Definitions » Price-to-Tangible-Book

Traws Pharma (Traws Pharma) Price-to-Tangible-Book : 1.26 (As of Apr. 29, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Price-to-Tangible-Book?

As of today (2024-04-29), Traws Pharma's share price is $0.64. Traws Pharma's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.51. Hence, Traws Pharma's Price to Tangible Book Ratio of today is 1.26.

The historical rank and industry rank for Traws Pharma's Price-to-Tangible-Book or its related term are showing as below:

TRAW' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.48   Med: 2.43   Max: 14.03
Current: 1.25

During the past 13 years, Traws Pharma's highest Price to Tangible Book Ratio was 14.03. The lowest was 0.48. And the median was 2.43.

TRAW's Price-to-Tangible-Book is ranked better than
78.28% of 1220 companies
in the Biotechnology industry
Industry Median: 2.65 vs TRAW: 1.25

A closely related ratio is called PB Ratio. As of today, Traws Pharma's share price is $0.64. Traws Pharma's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.51. Hence, Traws Pharma's P/B Ratio of today is 1.26.


Traws Pharma Price-to-Tangible-Book Historical Data

The historical data trend for Traws Pharma's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Price-to-Tangible-Book Chart

Traws Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.68 14.03 1.16 0.48 1.47

Traws Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.67 1.31 1.03 1.47

Competitive Comparison of Traws Pharma's Price-to-Tangible-Book

For the Biotechnology subindustry, Traws Pharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Price-to-Tangible-Book falls into.



Traws Pharma Price-to-Tangible-Book Calculation

Traws Pharma's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=0.64/0.508
=1.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Traws Pharma Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Traws Pharma's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Traws Pharma (Traws Pharma) Business Description

Traded in Other Exchanges
Address
12 Penns Trail, Newtown, PA, USA, 18940
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.
Executives
Victor M Moyo officer: CHIEF MEDICAL OFFICER 12 PENNS TRAIL, NEWTOWN PA 18940
Trafford Clarke director 12 PENNS TRAIL, NEWTOWN PA 18940
Peter Atadja director 12 PENNS TRAIL, NEWTOWN PA 18940
Abraham N. Oler officer: VP Corp Dev & Gen Counsel C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTERN AVENUE, SUITE 240, HENDERSON NV 89052
Steven M Fruchtman officer: Chief Medical Officer 375 PHEASANT RUN, NEWTOWN PA 18940
James J Marino director C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Gelder Mark S. Md officer: Chief Medical Officer C/O A.P. PHARMA, INC., 123 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mark Patrick Guerin officer: Chief Accounting Officer 375 PHEASANT RUN, NEWTOWN PA 18940
Mary Teresa Shoemaker director 375 PHEASANT RUN, NEWTOWN PA 18940
Michael B Hoffman director 1 GREENWICH OFFICE PARK, GREENWICH CT 06831
E Premkumar Reddy director 375 PHEASANT RUN, NEWTOWN PA 18940
Jerome Groopman director C/O GENTA INC, TWO CONNELL DR, BERKELEY HEIGHTS NJ 07922
Viren Mehta director OSI PHARMACEUTICALS INC, 58 S SERVICE RD STE 110, MELVILLE NY 11747
Tyndall Capital Partners L P 10 percent owner 150 EAST 58TH STREET, 14TH FLOOR, NEW YORK NY 10155
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022

Traws Pharma (Traws Pharma) Headlines